Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456417 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
A Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00456417 is a Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 30 participants.
The verdict
NCT00456417, a Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess 123-I MNI-187 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
Interventions
- DRUG 123-I MNI-187 Injection and Imaging Procedures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456417
The ClinicalTrials.gov registry entry for NCT00456417 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 123-I MNI-187 Injection and Imaging Procedures is the first listed.
NCT00456417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00456417 about?
NCT00456417 is a clinical study titled "Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects". The underlying goal of this study is to assess 123-I MNI-187 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
What is the current status of trial NCT00456417?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-04. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00456417?
The interventions under investigation include: 123-I MNI-187 Injection and Imaging Procedures (DRUG).
Who is sponsoring clinical trial NCT00456417?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.